Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-20

Clinical Trial Update: A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • cabozantinib (cabozantinib)

Snippet

Sponsor: Takeda | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-20